Randomized trial evaluates implementation strategies for cellular therapies in solid tumours and autoimmune diseases, indicating necessary institutional readiness.
Adoptive cellular therapies have revolutionised treatment of haematological malignancies and demonstrate potential in solid tumours and autoimmune disease. Real-world implementation remains limited by biological, logistical, and manufacturing barriers, restricting global uptake despite a rapidly expanding clinical trial portfolio. Effective implementation requires national and institutional readiness, multidisciplinary collaboration, scalable manufacturing, and robust infrastructure. Efforts should prioritise decentralised and “off the shelf” platforms, integrated referral networks, and AI-assisted patient management to support safe, equitable and efficient global delivery.
No takes yet. Share an insight, caveat, or question.
Childs et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: